Press Release

 View printer-friendly version
MyoKardia to Present at Two Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced its participation in the following upcoming investor conferences: 

  • Wells Fargo Securities 2017 Healthcare Conference in Boston, MA on Wednesday, September 6, 2017 at 10:15 a.m. ET
  • 2017 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Wednesday, September 27, 2017 at 8:00 a.m. ET

A live webcast of each presentation will be available by visiting the Investors section of MyoKardia’s website at A replay of both webcasts will be available on the MyoKardia website for 90 days following each conference.

About MyoKardia

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461). Mavacamten is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in Phase 1 clinical studies of HCM patients. In April 2016, the U.S. Food and Drug Administration granted Orphan Drug Designation for mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, a subset of HCM. MyoKardia is currently studying mavacamten in PIONEER-HCM. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.

Investor Contact:

Beth DelGiacco
Stern Investor Relations, Inc.

Media Contact:

Steven Cooper

Primary Logo

MyoKardia, Inc.